术前甲胎蛋白比值在肝癌射频消融术后预后评估中的作用。

Role of the pre- to postoperative alpha-fetoprotein ratio in the prognostic evaluation of liver cancer after radiofrequency ablation.

机构信息

Department of Hepatobiliary and Pancreas Surgery, ShenZhen People's Hospital(The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), ShenZhen, GuangDong, China.

Department of General Surgery, ShenZhen People's Hospital, ShenZhen, GuangDong, China.

出版信息

Int J Biol Markers. 2022 Sep;37(3):306-313. doi: 10.1177/03936155221101075. Epub 2022 Jun 9.

DOI:10.1177/03936155221101075

PMID:35686334

Abstract

OBJECTIVE

This study aimed to investigate the role of the alpha fetoprotein (AFP) ratio before and after radiofrequency ablation (RFA) in the prognosis of patients with liver cancer.

METHODS

A total of 368 patients who underwent RFA for liver cancer in Shenzhen People's Hospital from 2010 to 2020 were randomly divided into the training group and the validation group. Levels of AFP before and after RFA were recorded and their ratios were calculated.

RESULTS

Using the X-tile software, it was found that the optimal cut-off value of the AFP ratio in the training group was 37.9. Both in the training group and the validation group, the relapse-free survival and overall survival of patients with an AFP ratio <37.9 (high-risk group) were significantly shorter than those with an AFP ratio >37.9 (low-risk group) (training group, relapse-free survival, = 0.0003; overall survival, = 0.0186; validation group, relapse-free survival, = 0.0490, overall survival, = 0.0031). An AFP ratio <37.9 was an independent risk factor for recurrence and survival of liver cancer after RFA.

CONCLUSION

The AFP ratio can predict the prognosis of patients with liver cancer after RFA. An AFP ratio <37.9 is an independent risk factor for tumor recurrence and survival after RFA.

摘要

目的

本研究旨在探讨肝癌患者射频消融（RFA）前后甲胎蛋白（AFP）比值在预后中的作用。

方法

回顾性分析 2010 年至 2020 年在深圳市人民医院接受 RFA 治疗的 368 例肝癌患者的临床资料，采用随机数字表法将患者分为训练组和验证组。记录 RFA 前后 AFP 水平并计算其比值。

结果

采用 X-tile 软件分析，发现训练组 AFP 比值的最佳截断值为 37.9。在训练组和验证组中，AFP 比值<37.9（高风险组）的患者无复发生存和总生存时间均显著短于 AFP 比值>37.9（低风险组）（训练组，无复发生存，P=0.0003；总生存，P=0.0186；验证组，无复发生存，P=0.0490，总生存，P=0.0031）。AFP 比值<37.9 是 RFA 后肝癌复发和生存的独立危险因素。